Ginkgo Bioworks Holdings (DNA) Net Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Net Margin came in at 33.52% in Q1 2026, down 1352.0% YoY from 2.68% in Q1 2025, and up 86.14% on a QoQ basis from 241.8% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Net Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Net Margin data on file, last reported at 33.52% in Q1 2026.
- Quarterly Net Margin fell 1352.0% year-over-year to 33.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 161.58% (up 943.0% YoY) and the FY2025 annual result came in at 183.81%, up 5713.0% from the prior year.
- Net Margin improved to 33.52% in Q1 2026, from 241.8% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 20.0% in Q1 2025 to a low of 1009.26% in Q3 2022.
- A 5-year average of 285.85% and a median of 241.8% in 2025 frame the typical range for Net Margin.
- The widest YoY moves for Net Margin: up 90475 bps in 2022, down 87732 bps in 2022.
- Tracing DNA's Net Margin over 5 years: stood at 176.1% in 2022, then jumped by 51 bps to 87.09% in 2023, then sank by 182 bps to 245.25% in 2024, then rose by 1 bps to 241.8% in 2025, then soared by 86 bps to 33.52% in 2026.
- The last three Net Margin figures came in at 33.52% (Q1 2026), 241.8% (Q4 2025), and 207.93% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 52.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.64% |
| Mar 31, 2026 | -33.52% |
| Dec 31, 2025 | -241.80% |
| Sep 30, 2025 | -207.93% |
| Jun 30, 2025 | -121.56% |
| Mar 31, 2025 | -20.00% |
| Dec 31, 2024 | -245.25% |
| Sep 30, 2024 | -63.34% |
| Jun 30, 2024 | -386.40% |
| Mar 31, 2024 | -437.25% |
| Dec 31, 2023 | -87.09% |
| Sep 30, 2023 | -546.44% |
| Jun 30, 2023 | -215.12% |
| Mar 31, 2023 | -253.98% |
| Dec 31, 2022 | -176.10% |
| Sep 30, 2022 | -1,009.26% |
| Jun 30, 2022 | -463.68% |
| Mar 31, 2022 | -350.65% |
| Dec 31, 2021 | -1,080.85% |
| Sep 30, 2021 | -131.95% |